UMGCCC Clinical Trials

  • More About Clinical Trials
  • Deciding to Enroll
  • Questions to Ask
  • For More Information
  • Research
  • Cancer Overviews
  • Treatment Programs
  • Physicians and Staff
ProtocolsBack To Search Instructions
165 protocol(s) meet the specified criteria
Protocol No.TitleStatus
0848RTOGA Phase IIR and A Phase III Trial Evaluating Both Erlotinib (Ph IIR) And Chemoradiation (Ph III) As Adjuvant Treatment For Patients With Resected Head Of Pancreas AdenocarcinomaOpen
0858GCCVIRTUAL REALITY AND ACUTE PAIN MANAGEMENT FOR CHILDREN: PILOT TESTING OF VIRTUAL REALITY FOR INVASIVE MEDICAL PROCEDURES IN PEDIATRIC ONCOLOGY PATIENTS Open
0924RTOGAndrogen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized TrialOpen
1016GCCThe Role of NKT cells in Breast Cancer Patients and Healthy VolunteersOpen
1122GCCObservational Study of hepatic metastasis of colorectal originOpen
1150GCCA multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications.Open
1224GCCPhase II Trial of Low-Dose Whole Brain Radiotherapy with Concurrent Temozolomide and Adjuvant Temozolomide in Patients with Newly-Diagnosed Glioblastoma MultiformeOpen
1227GCCIrreversible electroporation for locally advanced unresectable pancreatic cancer.Open
1304RTOG/NSABP-B-51A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant ChemotherapyOpen
1314GCCPhase II Trial of Low Dose Whole Pelvic Radiotherapy with Concurrent Neoadjuvant FOLFOX for Patients with Newly Diagnosed T3N0M0, T2N1M0, and T3N1M0 Rectal AdenocarcinomaOpen
1324GCCNeoadjuvant FOLFIRINOX and Stereotactic Body Radiotherapy (SBRT) Followed by Definitive Surgery for Patients with Borderline Resectable Pancreatic Adenocarcinoma: A Single-Arm Pilot Study Open
1344GCCPILOT STUDY OF COMBINED OPTUNE, BEVACIZUMAB, AND HYPOFRACTIONATED STEREOTACTIC IRRADIATION FOR BEVACIZUMAB-NAIIVE, RECURRENT GLIOBLASTOMA Open
1366GCCA PROSPECTIVE STUDY OF NEOADJUVANT NON-STEROIDAL AROMATASE INHIBITORS IN POSTMENOPAUSAL WOMEN WITH OPERABLE HORMONE RECEPTOR-POSITIVE BREAST CANCER TO EVALUATE THE ANTI-PROLIFERATIVE RESPONSE IN OBESE AND OVERWEIGHT PATIENTSOpen
1403GCCAn Umbrella Protocol for Collection of Blood, Tumor Tissue, Lymph Node Specimens, normal tissue, effusions CSF fluid and Buccal Samples from Patients with Established or Suspected Solid Tumor Malignancy and Normal Subjects, to be used in Laboratory ResearchOpen
1424GCCA Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Age 50 or Older with Intermediate-2 and High Risk Myelodysplastic SyndromeOpen
1425GCCInhibition of Pim kinases in acute myeloid leukemia Open
1455GCCAn Umbrella Protocol for Collection of Blood Samples from Patients Undergoing Craniotomy or Stereotactic Brain Biopsy, to be used in Laboratory ResearchOpen
1456GCCA Phase II trial of reirradiation combined with open label Pembrolizumab in patients with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck (SCCHN)Open
1495GCCAn Umbrella Protocol for the Collection of Blood and Biological Samples from Patients with Established or Suspected Thoracic Malignancies and Normal Subjects, to Be Used in Laboratory ResearchOpen
15100GCCPragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium TrialOpen
1530GCCA Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of DosesOpen
1532GCCPhase I Study of C6 Ceramide Nanoliposome in Patients with Advanced Solid TumorsOpen
1534GCC A pilot study to evaluate inflammatory markers in patients receiving pelvic radiation therapy and Pediococcus-based probioticsOpen
1547GCCULTRASOUND-BASED BLADDER SCANNING FOR REPRODUCIBILITY OF BLADDER-FILLING DURING ABDOMINOPELVIC EXTERNAL BEAM RADIOTHERAPYOpen
1550GCCRandomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After ChemotherapyOpen
1554GCCA Phase 1/2 Study of INCB053914 in Subjects With Advanced MalignanciesOpen
1556GCCA Phase I Dose Escalation Open-Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC).Open
1557GCCImpact of construal on demand for cigarettesOpen
1562GCCA Phase 1 Trial of Indoximod in Combination with Idarubicin and Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) [NLG-2106]Open
1563GCCMitigation of radiation pneumonitis and fibrosisOpen
1565GCCMulticenter phase 1/2 study of combination therapy with the DNA methyltransferase inhibitor decitabine and the poly ADP ribose polymerase (PARP) inhibitor talazoparib (BMN 673) for untreated acute myeloid leukemia (AML) in adult patients unfit for cytotoxic chemotherapy or relapsed/refractory AMLOpen
1567GCCA Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) Open
1569GCCA Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung CancerOpen
1570GCCPhase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer Open
1571GCCPhase II Study of Postoperative, Cardiac-Sparing Proton Radiotherapy for Patients with Stage II/III, Loco-Regional, Non-Metastatic Breast Cancer Requiring Whole Breast or Chest Wall Irradiation with Lymph Node IrradiationOpen
1578GCCPhase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Cisplatin and Pemetrexed. NCI 9837, PhI-76Open
1579GCCA Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating AgentOpen
1583GCCA Phase III Prospective Randomized Trial of Standard-fractionation vs. Hypo-fractionation with Proton Radiation Therapy for Low Risk Adenocarcinoma of the Prostate Open
1590GCCA Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid or Hematological MalignanciesOpen
16101GCCA Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4Open
16105GCCDirect Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) [AFT-28]Open
16106GCCNational Mesothelioma Virtual Registry and Tumor Bank: Continued InnovationOpen
16110GCCA Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell TransplantationOpen
16111GCCA Phase I Open Label, Clinical Trial Evaluating the Safety and Anti-tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha-fetoprotein (AFPc332T) in HLA-A2 Positive Subjects with Advanced Hepatocellular Carcinoma (HCC) Open
16114GCCMETIS: Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC).Open
16115GCCIntegration of Cancer Health Activities into African American ChurchesOpen
16118GCCA Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD) Open
1611GCCPhase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell/Myeloma FusionOpen
1614GCC Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)Open
1618GCCCARDIAC MAGNETIC RESONANCE IMAGING AND BIOMARKER TESTING FOR EVALUATING CARDIAC INJURY RESULTING FROM RADIATION THERAPY IN LUNG AND BREAST CANCER: A PILOT STUDYOpen
1626GCCA Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation TherapyOpen
1630GCCA Pilot study of Zydelig in Patients with B-cell Malignancies as Post-Autologous Transplant Remission MaintenanceOpen
1632GCCA Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 MutationOpen
1635GCC Investigating Radiation-Induced Injury to Airways and Pulmonary Vasculature in Lung Stereo-tactic Ablative Body Radiotherapy (SAbR) Open
1641GCCA Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell LymphomaOpen
1642GCCA Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal CancerOpen
1649GCCAllogeneic hematopoietic stem cell transplantation for severe aplastic anemia and other bone marrow failure syndromes using G-CSF mobilized CD34+ selected hematopoietic precursor cells co-infused with a reduced dose of non-mobilized donor T-cells Open
1652GCCPhase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)Open
1654GCCPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)Open
1657GCCPhase 1 and Pharmacology Study of Oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases Open
1665GCC1665GCC: An Umbrella Protocol for the Collection of Blood and Biological Samples from Patients with Established or Suspected Gastrointestinal Malignancies, Mesothelioma, and Normal Subjects to Be Used in Laboratory ResearchOpen
1666GCCA Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (with Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients with High-Risk Squamous Cell Carcinoma of the Oral CavityOpen
1671GCCA Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR AlterationsOpen
1676GCCA Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating AgentsOpen
1680GCCA Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial CancerOpen
1683GCCA Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast CancerOpen
1685GCC Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for the treatment of Oropharyngeal Cancer of the Head and Neck Open
1686GCCA Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects with Relapsed/Refractory Aggressive B-Cell Non Hodgkin LymphomaOpen
1687GCCPARTIQoL: Prostate Advanced Radiation Technologies Investigating Quality of Life; A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer. Open
1693GCC-EU1693GCC-EU Compassionate use of ASP2215 in patient PBOpen
1695GCCUMGCCC Data and Biosample Repository and Maryland Cancer Survivorship CohortOpen
1699GCCA Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination with Azacitidine in Subjects with Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS) [M15-531]Open
1704GCCA Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine [15-102-14]Open
1707GCCCAn Open-Label Phase 1/2 Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell LymphomaOpen
1708GCCA Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination DeficiencyOpen
17102GCCC17102GCCC: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast CancerOpen
17104GCCC17104GCCC: A phase III, randomized, double-blinded, placebo-controlled, multi-center study evaluation the safety, tolerability and efficacy of combination treatment of BL-8040 and G-CSF as compared to placebo and G-CSF for the mobilization of hematopoietic stem cells for autologous transplantation in subjects with multiple myeloma-The Genesis Study. Open
17106GCCCA Phase 1 Dose-Escalation Study of LAM 003 in Patients with Acute Myeloid Leukemia [LAM-003-HEM-CLN02]Open
17115GCCC17115GCCC: A phase 2, multicenter, open-label study to assess PK/PD of SEG101 (crizanlizumab), with or without hydroxyurea/hydroxycarbamide, in adult sickle cell patients with vaso-occlusive crisisOpen
17116GCCC17116GCCC: ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate CancerOpen
17117GCCC17117GCCC: GRAVITAS-119: A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus-Host Disease Not Open
17118GCCC17118GCCC A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (POLARIX)Not Open
17119GCCC17119GCCC:Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT): A phase 2 trial of induction, consolidation and maintenance in subjects with high risk smoldering multiple myeloma (SMM) Open
1711GCCCNeoadjuvant Anti-PD-L1 (Durvalumab/MEDI4736) Plus Anti-CTLA-4 (Tremelimumab) and Radiation for High Risk Soft-Tissue SarcomaOpen
1712GCCA Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate CancerOpen
1717GCCA Ketogenic Diet Pilot Study for Overweight Prostate Cancer Patients on Active SurveillanceOpen
1718GCCC-M1A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)Open
1718GCCC-S2Phase Ib/II Study of BI 836858 with Azacitidine in Previously Untreated AML Patients >/=60 Years With Unique Molecular Features [BAML-16-001-S2]Open
1718GCCC-S3A Phase II Study to Assess the Efficacy of the Treatment of IDH2 Mutant AML with Targeted IDH2 Inhibition and Subsequent Response-Driven Addition of Hypomethylating Agent Therapy [BAML-16-001-S3]Open
1718GCCC-S4A Phase 1b/2 Study of Entospletinib (ENTO) in Patients with Acute Myeloid Leukemia (AML) > Age 60 with Mixed Lineage Leukemia (MLL) Gene Re-arrangements and/or MLL-Partial Tandem Duplications (MLL-PTD)Open
1718GCCC-S5A Phase 2 Study of Entospletinib and Decitabine Targeting Mutant TP53 and or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia >/= Age 60 yearsOpen
1718GCCC-S6A Phase 2 Study of Entospletinib in NPM1 mutant/FLT3 ITD Wild Type AML Patients Age >/= 60 yearsOpen
1718GCCC-S9Phase 2 Study with Pevonedistat in combination with Azacitidine targeting NEDD8-activating enzyme (NAE) in TP53 Mutant Untreated Acute Myeloid Leukemia patients >/= 60 years of ageOpen
1719GCCC1719GCCC: A PHASE 3 RANDOMIZED, CONTROLLED, OPEN-LABEL STUDY OF SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE (SVD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)Open
1720GCCCExpanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)Open
1723GCCCTRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination DeficiencyOpen
1732GCCA Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemo-radiation Therapy for Non-Small Cell Lung Cancer (NSCLC) Open
1743GCCCA Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast CancerOpen
1750GCCCAn Open-Label, Multi-Center, Randomized, Dose-Escalation, Phase 1b Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281, in Combination With Atezolizumab ± Bevacizumab, in Patients With Unresectable Advanced and/or Metastatic Renal Cell CarcinomaOpen
1754GCCCAssessment of the cognitive effects of chemotherapy in breast cancer patientsOpen
1758GCCA Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients Open
1759GCCCA Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell LymphomaOpen
1767GCCCOpen-Label Randomized Pilot Study To Assess The Safety, Tolerability And Antitumor Activity Of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone Or In Combination With Pembrolizumab In HLA-A2+ Subjects With NY-ESO-1 And/Or LAGE 1A Positive Relapsed And Refractory Multiple MyelomaOpen
1768GCCBiobehavioral Mechanisms of Breast Cancer Racial DisparitiesOpen
1773GCCCGRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host DiseaseOpen
1775GCCCDNA methylation at chromosome 8q24 and the risk of aggressive prostate canceOpen
1778GCCC1778GCCC: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)Open
1779GCCCPhase 1/2 Study of TEW-7197 Monotherapy in Patients with Low or Intermediate Myelodysplastic Syndromes (MDS) Open
1783GCCC1783GCCC: Use of plerixafor (mozobil) for stem cell mobilization and its effect on outcome in multiple myeloma patients who have undergone autologous stem cell transplantationOpen
1784GCCCA Phase 1/2 Open-label Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 TrialOpen
1790GCCCAn Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With MyelofibrosisOpen
1791GCCC1791GCCC: A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, TRIPLE-NEGATIVE BREAST CANCER OR HORMONE RECEPTOR–POSITIVE, HER2-NEGATIVE BREAST CANCEROpen
1793GCCCA Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation Open
1797GCCC1797GCCC: Randomized, Double-Blind, Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study) [POLARIS2015-003]Open
1800GCCCA Phase I/II multicenter study combining guadecitabine, a DNA methyltransferase inhibitor, with Atezolizumab, an immune checkpoint inhibitor, in patients with intermediate or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia.Open
1818GCCCA Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7) Open
1824GCCC1824GCCC: ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial CarcinomaOpen
30610CALGBPhase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and EtoposideOpen
341256Implementation of evidence-based cancer early detection in Black churches (accrual complete before 2015)Open (affiliates only)
380462Behavioral Intervention to Reduce Breast Cancer Disparity in Under served KoreansOpen (affiliates only)
71577A Novel model of Hepatitis C Treatment as Anchor to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky BehaviorOpen
A011106ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III studyOpen
A011202A RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF AXILLARY LYMPH NODE DISSECTION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPYOpen
A011401Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast CancerOpen
A011502Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation TherapyOpen
A021502A021502 Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch RepairOpen
A081105ALCHEMIST: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)Open
A151216Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)Open
A211401Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients who Smoke Cigarettes Open
A221505Phase III Randomized Trial of Hypo-fractionated Post Mastectomy Radiation with Breast Reconstruction (Alliance trial)Open
AALL1231A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)Open
AALL1331Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)Open
AAML1331A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid. Open
AEWS1221Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing SarcomaOpen
AGCT1531AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors Open
AHOD1331A Randomized Phase III Study of Brentuximab Vedotin (Bv, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and AdolescentsOpen
AM0010-301A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First- Line Gemcitabine Containing RegimenOpen
APEC14B1THE PROJECT: EVERYCHILD PROTOCOL: A REGISTRY, ELIGIBILITY SCREENING, BIOLOGY AND OUTCOME STUDYOpen
APEC1621APEC1621: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening ProtocolOpen
E1910A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in AdultsOpen
E2112A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast CancerOpen
E4512ALCHEMIST: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion ProteinOpen
EA5142Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung CancersOpen
EAY-131EAY- 131 Molecular Analysis for Therapy Choice (MATCH) Open
GI001RANDOMIZED PHASE III STUDY OF FOCAL RADIATION THERAPY FOR UNRESECTABLE, LOCALIZED INTRAHEPATIC CHOLANGIOCARCINOMA Open
N1048PROSPECT: A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal ExcisionOpen
NHLBI-MDSA prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural HistoryOpen
NRG-BN001RANDOMIZED PHASE II TRIAL OF HYPOFRACTIONATED DOSE-ESCALATED PHOTON IMRT OR PROTON BEAM THERAPY VERSUS CONVENTIONAL PHOTON IRRADIATION WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMAOpen
NRG-BR002A Phase IIR/III Trial of Standard of Care with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast CancerOpen
NRG-BR003A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer Open
NRG-GU002Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel Open
NRG-GY005Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)Open
NRG-HN002A RANDOMIZED PHASE II TRIAL FOR PATIENTS WITH p16 POSITIVE, NON-SMOKING ASSOCIATED, LOCOREGIONALLY ADVANCED OROPHARYNGEAL CANCER Open (affiliates only)
NRG-LU002 MAINTENANCE SYSTEMIC THERAPY VERSUS CONSOLIDATIVE STEREOTACTIC BODY RADIATION THERAPY (SBRT) PLUS MAINTENANCE SYSTEMIC THERAPY FOR LIMITED METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE II/III TRIAL Open
NSABP-B-55A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib vs. Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant ChemotherapyOpen
POLARISPOLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional StudyOpen
S0820A Double Blind Placebo-Controlled Trial of Eflornithine andSulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)Open
S1418A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant ChemotherapyOpen
S1501Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast CancerOpen
SWOG1207Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine TherapyOpen
SWOG1400S1400 PHASE II/III BIOMARKER-DRIVEN MASTER PROTOCOL FOR SECOND LINE THERAPY OF SQUAMOUS CELL LUNG CANCEROpen
SWOG1400FA PHASE II STUDY OF MEDI4736 (DURVALUMAB) PLUS TREMELIMUMAB AS THERAPY FOR PATIENTS WITH PREVIOUSLY TREATED ANTI-PD-1/PD-L1 RESISTANT STAGE IV SQUAMOUS CELL LUNG CANCER (LUNG-MAP NON-MATCH SUB-STUDY)Open
SWOG1400GA PHASE II STUDY OF TALAZOPARIB (BMN 673) IN PATIENTS WITH HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY POSITIVE STAGE IV SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY)Open (affiliates only)
SWOG1400IA Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-Study)Open (affiliates only)
SWOG1400KSWOG1400K: A PHASE II STUDY OF ABBV-399 (Process II) IN PATIENTS WITH C-MET POSITIVE STAGE IV OR RECURRENT SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY)Open (affiliates only)